While Astrazeneca plc ADR has underperformed by -0.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AZN fell by -2.54%, with highs and lows ranging from $87.68 to $60.47, whereas the simple moving average fell by -11.06% in the last 200 days.
On November 20, 2024, UBS Upgraded Astrazeneca plc ADR (NASDAQ: AZN) to Neutral. A report published by Deutsche Bank on November 06, 2024, Upgraded its rating to ‘Hold’ for AZN. Goldman Initiated an Buy rating on May 30, 2024, and assigned a price target of $97. Deutsche Bank April 16, 2024d its ‘Sell’ rating to ‘Hold’ for AZN, as published in its report on April 16, 2024. Morgan Stanley also rated the stock as ‘Overweight’.
Analysis of Astrazeneca plc ADR (AZN)
It’s important to note that AZN shareholders are currently getting $1.48 per share in dividends, so investors will receive a return regardless of how the company performs. Further, the quarter-over-quarter increase in sales is 18.04%, showing a positive trend in the upcoming months.
Astrazeneca plc ADR’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of 16.67% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.71, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and AZN is registering an average volume of 5.61M. On a monthly basis, the volatility of the stock is set at 1.33%, whereas on a weekly basis, it is put at 1.04%, with a gain of 1.63% over the past seven days. Furthermore, long-term investors anticipate a median target price of $86.20, showing growth from the present price of $66.64, which can serve as yet another indication of whether AZN is worth investing in or should be passed over.
How Do You Analyze Astrazeneca plc ADR Shares?
A giant in the Drug Manufacturers – General market, Astrazeneca plc ADR (AZN) is based in the United Kingdom. When comparing Astrazeneca plc ADR shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 32.02, there is a growth in quarterly earnings of 3.86%.
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.03%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 15.80% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AZN shares are owned by institutional investors to the tune of 15.80% at present.
